Private Eye

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Off-market insider buying at Satellos Bioscience (V:MSCL)

Updated Monday Sep 19, 2022 03:02 AM EDT

William Wasyl Jarosz, a Director, acquired 325,000 Common Shares on a direct ownership basis at a price of $0.400 through a prospectus or prospectus exempt offering on September 13th, 2022. The insider also acquired 162,550 Warrants on a direct ownership basis at an exercise price of $0.600 through a prospectus or prospectus exempt offering on September 13th, 2022. This represents a $130,000 investment into the company's shares and an account share holdings change of greater than 100%.

Satellos Bioscience is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Satellos Bioscience Inc. is a Canada-based biotechnology and drug development company. The Company is focused on developing medicines to treat degenerative muscle conditions. The Company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. It uses MyoReGenX discovery platform to map pathways which modulate muscle repair and regeneration, identify and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its iCo Portfolio consists of two technologies namely the Oral Amp B Delivery System and Bertilimumab (previously iCo-008). Bertilimumab is a human monoclonal antibody that neutralizes eotaxin-1, a ligand to the C-C chemokine receptor type three to treat a range of allergic and inflammatory conditions.

INK Edge Outlook

6 months ago
1 year ago
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at
Two-week free trial for first time users.
Go to Satellos Bioscience Inc. (MSCL)'s company page

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).

Comment On!

No Comments


Search (past week) for $MSCL.CA


Satellos Bioscience Inc.

  • Symbol not found.